184 related articles for article (PubMed ID: 35185147)
1. Successful Treatment for Isolated Bone Marrow Hodgkin Lymphoma in an Human Immunodeficiency Virus (HIV)-Negative Patient.
Odeh R; Hamayel HF
Am J Case Rep; 2022 Feb; 23():e935045. PubMed ID: 35185147
[TBL] [Abstract][Full Text] [Related]
2. A successful initiation of treatment of Hodgkin's lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immunodeficiency virus and hepatitis B.
Veeraballi S; Chan KH; Slim J; Shaaban HS; Guron G
J Oncol Pharm Pract; 2022 Mar; 28(2):479-485. PubMed ID: 34590528
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.
Nagaharu K; Masuya M; Kageyama Y; Yamaguchi T; Ito R; Kawakami K; Ito M; Katayama N
J Med Case Rep; 2018 May; 12(1):151. PubMed ID: 29843820
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of Hodgkin's lymphoma: at times a challenge.
Abbasi NZ; Jalal-ud-Din M; Zahur Z; Khan AA; Sheikh AS; Ali F; Memon KH
J Coll Physicians Surg Pak; 2013 Oct; 23(10):752-3. PubMed ID: 24112267
[TBL] [Abstract][Full Text] [Related]
6. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
7. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
[TBL] [Abstract][Full Text] [Related]
9. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
10. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
[TBL] [Abstract][Full Text] [Related]
11. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
Arakelyan N; Jais JP; Tomowiack C; Colombat P; Berthou C; Desablens B; Moles-Moreau MP; Gastinne T; Quittet P; Casassus P; Le Pourhiet-Le Mevel A; Ghandour C; Brière J; Colonna P; Andrieu JM
Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
[TBL] [Abstract][Full Text] [Related]
12. Primary bone marrow Hodgkin lymphoma in an HIV-negative patient.
Dholaria B; Alapat D; Arnaoutakis K
Int J Hematol; 2014 Apr; 99(4):503-7. PubMed ID: 24532438
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
Hutchings M; Radford J; Ansell SM; Illés Á; Sureda A; Connors JM; Sýkorová A; Shibayama H; Abramson JS; Chua NS; Friedberg JW; Kořen J; LaCasce AS; Molina L; Engley G; Fenton K; Jolin H; Liu R; Gautam A; Gallamini A
Hematol Oncol; 2021 Apr; 39(2):185-195. PubMed ID: 33462822
[TBL] [Abstract][Full Text] [Related]
14. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary.
McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE
Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
[TBL] [Abstract][Full Text] [Related]
16. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
17. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
18. A Prolonged Activated Partial Thromboplastin Time in a Child With Hodgkin Lymphoma.
Kara B; Kart KK; Koksal Y
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e401-e403. PubMed ID: 32000198
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of Hodgkin lymphoma in second trimester of pregnancy: feasibility of ABVD regimen.
Iriyama N; Horikoshi A; Tanaka T; Hirabayashi Y; Kodaira H; Hatta Y; Takeuchi J
Int J Hematol; 2011 Jul; 94(1):104-107. PubMed ID: 21643694
[TBL] [Abstract][Full Text] [Related]
20. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
